Therapy: Targeted but not trouble-free: efalizumab and PML.
Level V
Where this comes from
- Record sourced from PubMed, PMID 19648939.
- Also identified by DOI 10.1038/nrrheum.2009.142.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In April 2009, efalizumab was withdrawn from the market for the treatment of psoriasis after reports emerged of an association between long-term therapy and the development of progressive multifocal leukoencephalopathy (PML). This event highlights an urgent need for greater awareness and research into the screening, diagnosis and treatment of this potentially fatal disease in patients undergoing immunosuppressive therapy for chronic inflammatory disorders.
Medical subject headings
- Antibodies, Monoclonal
- Leukoencephalopathy, Progressive Multifocal